White Pine Capital LLC Acquires 42,512 Shares of Codexis, Inc. (NASDAQ:CDXS)

White Pine Capital LLC grew its stake in Codexis, Inc. (NASDAQ:CDXS) by 28.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 193,936 shares of the biotechnology company’s stock after purchasing an additional 42,512 shares during the period. White Pine Capital LLC owned approximately 0.24% of Codexis worth $925,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new position in Codexis in the fourth quarter valued at about $82,000. Kingswood Wealth Advisors LLC bought a new position in shares of Codexis in the fourth quarter valued at approximately $79,000. Inspire Investing LLC bought a new position in shares of Codexis in the fourth quarter valued at approximately $405,000. Jackson Square Capital LLC acquired a new position in shares of Codexis in the 4th quarter worth approximately $210,000. Finally, Tallon Kerry Patrick bought a new stake in Codexis during the 4th quarter worth approximately $2,018,000. 78.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CDXS. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price objective on shares of Codexis in a research report on Friday, November 22nd. Benchmark reaffirmed a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Codexis Price Performance

CDXS opened at $4.10 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The company’s 50 day simple moving average is $4.85 and its 200-day simple moving average is $3.89. Codexis, Inc. has a one year low of $2.56 and a one year high of $6.08. The stock has a market capitalization of $333.66 million, a P/E ratio of -4.71 and a beta of 2.12.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.